Elif E Firat, Alark Joshi, Robert S Laramee, Beatriz Sousa Santos, Ginger Alford
VisLitE: Visualization Literacy and Evaluation
IEEE computer graphics and applications
malaria treatment subsaharan africa faced challenges including unreliable supply efficacious agents substandard medicines coupled high price artemisininbased combinations affects access effective treatment increasing risk malaria parasite resistance development adverse drug events study investigated access qualityassured artemisininbased combination therapy qaact medicines among clients selected private drugoutlets uganda cross sectional study exit interviews conducted among clients private drug outlets low high malaria transmission settings uganda study adapted world health organizationhealth action international whohai standardized criteria data collected using validated questionnaire data entry screen checks created epidata ver 42 software data entered duplicate data transferred stata ver 140 cleaned prior analysis analysis done 95 level significance total 1114 exit interviews conducted among systematically sampled drug outlet clients half 549 6111114 participants males majority 972 10831114 purchased artemisininbased combination antimalarial 555 6181114 participants laboratory diagnosis malaria majority 779 8681114 participants obtained antimalarial agents without prescription less third 277 3091114 participants obtained qaact participants obtained qaact half 569 173309 reported finding medicine expensive predictors accessing qaact antimalarial among drug outlet clients include type drug outlet visited apr 074 95ci 06 091 obtaining full dose 3day treatment act apr 049 95ci 033 073 finding act expensive apr 124 95ci 103 149 postprimary education apr 129 95ci 107156 business occupation apr 124 95ci 102150 prescription apr 076 95ci 063 092 less third private drug outlet clients obtained qaact management malaria symptoms individuals find artemisininbased combinations expensive likely obtain qaact antimalarial ministry health needs conduct regular surveillance monitor accessibility qaact antimalarial agents current private sector copayment mechanism